Hawaii Biotech, Inc., (Honolulu, HI), has been notified by the United States Food and Drug Administration (FDA) that it may initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.
Hawaii Biotech, Inc. (Honolulu, HI), has been notified by the United States Food and Drug Administration (FDA) that it may initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008. Depending on the actual start date, results of the trial may be available by the end of 2008.
There is currently no vaccine for the prevention of West Nile disease in humans, a disease that has caused over 25,000 cases of disease and over 1,000 deaths since it was introduced in the US in 1999.
